nach oben

Pituitary

Erschienen in:

01.06.2011

Analysis of thrombophilic genetic mutations in patients with Sheehan`s syndrome: is thrombophilia responsible for the pathogenesis of Sheehan`s syndrome?

verfasst von: Deniz Gokalp, Alpaslan Tuzcu, Mithat Bahceci, Orhan Ayyildiz, Murat Yurt, Yusuf Celik, Gulistan Alpagat

Erschienen in: Pituitary | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

The gene mutations of Factor V R506Q (FV-Leiden), prothrombin (FII G20210A), methylene tetrahydrofolate reductase (MTHFR) C677T and A1298C and PAI-1 4G/5G are well-established risk factors for thrombosis. We aimed to investigate the prevalence of these gene mutations and their possible impact on the development of pathogenesis in patients with Sheehan’s syndrome (SS). 40 female patients with SS compared to a control group of 45 healthy women. The presence of FV-Leiden, FII G20210A, MTHFR C677T, MTHFR A1298C and PAI-1 4G/5G gene mutations were assessed by polymerase chain reaction analysis with a light cycler analyzer. An odds ratio of greater than one is considered to increase the risk of SS disease as found in Factor V Leiden, FII G20210A, MTHFR C677T, MTHFR A1298C and PAI-1 4G/5G polymorphism, as follows respectively: 1.13, 1.85, 6.00, 8.14 and 1.45. MTHFR C677T and MTHFR A1298C polymorphism were found significantly higher in SS patients than the control group (P < 0.001), however FV-Leiden, FII G20210A and PAI-1 4G/5G polymorphism showed no significant difference (P > 0.05). The level of plasma total homocysteine (tHcy) was significantly higher in patients with SS than in the control group (P < 0.001). We suggest that the genetic mutations of FV-Leiden, FII G20210A, MTHFR C677T, MTHFR A1298C and PAI-1 4G/5G increase the risk of SS. Also, high plasma tHcy levels may be a risk factor for the development of SS.

Sheithauer B, Sano T, Kovacs K, Young W Jr, Ryan N, Randall R (1990) The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 patients. Mayo Clin Proc 65(4):461CrossRef

Goswami R, Kochupillai N, Crock P, Jaleel A, Gupta N (2002) Pituitary autoimmunity in patients with Sheehans syndrome. J Clin Endocr Metab 87(9):4137CrossRefPubMed

Kelestimur F (2003) Sheehan’s syndrome. Pituitary 6:181–188CrossRefPubMed

Carp H, Salomon O, Seidman D, Dardik R, Rosenberg N, Inbal A (2002) Prevalence of genetic markers for thrombophilia in recurrent pregnancy loss. Hum Reprod 17:1633–1637CrossRefPubMed

Bick RL, Hoppensteadt D (2005) Recurrent miscarriage syndrome and infertility due to blood coagulation protein/platelet defects: a review and update. Clin App Thromb Hemost 11:1–13CrossRef

Foka ZJ, Lambropoulos AF, Saravelos H et al (2000) Factor V Leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum Reprod 15:458–462CrossRefPubMed

den Heijer M, Koster T, Blom HJ et al (1996) Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334:759–762CrossRef

Tassies D, Espinosa G, Munoz-Rodriguez FJ et al (2000) The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthritis Rheum 43:2349–2358CrossRefPubMed

Stegnar M, Uhrin P, Peternel P et al (1998) The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 79:975–979PubMed

10.

Sheehan HL (1937) Postpartum necrosis of the anterior pituitary. J Path Bacteriol 45:189–214CrossRef

11.

Veldhuis JD, Hammond JM (1980) Endocrine function after spontaneous infarction of the human pituitary: report, review, and reappraisal. Endocr Rev 1(1):100–107CrossRefPubMed

12.

Di Ziegra D, Kletzky DA, Mishell DR (1978) Diagnosis of Sheehan’s syndrome using sequental pituitary stimulation tests. Am J Obstet Gynecol 132:348–353CrossRef

13.

Roberts DM (1998) Sheehan’s syndrome. Am Fam Physician 244:261–266

14.

Gupta D, Gaiha M, Mahajan R, Daga MK (2001) Atypical presentation of sheehan’s syndrome without postpartum hemorrhage. J Assoc Physicians India 49:386–387PubMed

15.

Kovacs K (2003) Sheehan syndrome. Lancet 361:520–522CrossRefPubMed

16.

Kalkanli S, Ayyildiz O, Tiftik N, Batun S, Isikdogan A et al (2006) Factor V Leiden mutation in venous thrombosis in southeast Turkey. Angiology 57(2):193–196CrossRefPubMed

17.

Gurgey A, Mesci L (1997) The prevalence of factor V Leiden (1691G → A) mutation in Turkey. Turk J Pediatr 39:313–315PubMed

18.

Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M et al (1998) Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 79:706–708PubMed

19.

Ayyildiz O, Kalkanli S, Batun S, Aybak M, Isikdogan A, Tiftik N, Bolaman Z, Soker M, Muftuoglu E (2004) Prothrombin G20210A gene mutation with Lightcycler polymerase chain reaction in venous thrombosis and healthy population in the southeast of Turkey. Heart Vessels 19:164–166CrossRefPubMed

20.

Akar N, Misirlioglu M, Akar E, Avci F, Yalcin A (1998) Prothrombin gene 20210 G-A mutations in Turkish population. Am J Hematol 58:249CrossRefPubMed

21.

Castoldi E, Rosing J (2004) Factor V Leiden: a disorder of factor V anticoagulant function. Curr Opin Hematol 11(3):176–181CrossRefPubMed

22.

Bloemenkamp KW, Rosendaal FR, Helmerhorst FM et al (1995) Enhancement by factor V Leiden mutation of risk of deep vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346:1593–1596CrossRefPubMed

23.

Rosendaal FR, Koster T, Vandenbroucke JP et al (1995) High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 86:4700–4702

24.

Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703PubMed

25.

Wald D, Law M, Morris J (2002) Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Brit Med J 325:1202–1208CrossRefPubMedPubMedCentral

26.

Quere I, Perneger T, Zittoun J, Bellet H, Gris JC, Daures JP et al (2002) Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study. Lancet 359:747–752CrossRefPubMed

27.

Hainaut P, Jaumotte J, Verhelst D, Wallemacq P, Gala JP, Lavenne E et al (2002) Hyperhomocysteinemia and venous thromboembolism: a risk factor more prevalent in the elderly and in idiopathic cases. Thromb Res 106(2):121–125CrossRefPubMed

28.

Eichinger S, Stumpflen A, Hirschi M, Bialonczyk C, Herkner K, Stain M et al (1998) Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 80(4):566–569PubMed

29.

van der Put NM, Gabreels F, Stevens EM et al (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural ltube defects? Am J Hum Genet 62:1044–1051CrossRefPubMedPubMedCentral

30.

Weisberg I, Tran P, Christensen B et al (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64:169–172CrossRefPubMed

31.

den Heijer M, Lewington S, Clarke R (2005) Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. Thromb Haemost 3:292–299CrossRef

32.

Dossenbach-Glaninger A, van Trotsenburg M, Dossenbach M et al (2003) Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss. Clin Chem 49(7):1081–1086CrossRefPubMed

33.

Segui R, Estelles A, Mira Y et al (2000) PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol 111(1):122–128CrossRefPubMed

Titel: Analysis of thrombophilic genetic mutations in patients with Sheehan`s syndrome: is thrombophilia responsible for the pathogenesis of Sheehan`s syndrome?
verfasst von: Deniz Gokalp
Alpaslan Tuzcu
Mithat Bahceci
Orhan Ayyildiz
Murat Yurt
Yusuf Celik
Gulistan Alpagat
Publikationsdatum: 01.06.2011
Verlag: Springer US
Erschienen in: Pituitary / Ausgabe 2/2011
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-010-0276-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

The comparison of low and standard dose ACTH and glucagon stimulation tests in the evaluation of hypothalamo-pituitary-adrenal axis in healthy adults

Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR

Erratum to: Retrospective multicentric study of pituitary incidentalomas

Primary CNS lymphoma with bilateral symmetric hypothalamic lesions presenting with panhypopituitarism and diabetes insipidus

Transnasal trans-sphenoidal endoscopic repair of CSF leak secondary to invasive pituitary tumours using a nasoseptal flap